Biofil Chemicals & PharmaceuticalsBOM:524396 65 Operating Margin % is 4.76% as of Mar. 2026, which is 54% above its 10-year median of 3.09. GuruFocus rates BOM:524396 with a GF Score™ of 65/100 and a GF Value™ of ₹41.83 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Biofil Chemicals & Pharmaceuticals ranks worse than 67.12% on this metric.
Biofil Chemicals & Pharmaceuticals Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -21.8%.
The historical rank and industry rank for Biofil Chemicals & Pharmaceuticals's Operating Margin % or its related term are showing as below:
BOM:524396'
s Operating Margin % Range Over the Past 10 Years
Min: 1.04 Med: 3.09 Max: 17.36
Current: 1.33
BOM:524396's Operating Margin % is ranked worse than 67.12% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.58
vs BOM:524396: 1.33
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Biofil Chemicals & Pharmaceuticals Operating Margin % Related Terms
Biofil Chemicals & Pharmaceuticals Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (BOM:524396) has a Operating Margin % of 4.76% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. This is 54% above median its historical median of 3.09. Over the past decade, Biofil Chemicals & Pharmaceuticals' Operating Margin % has ranged from 1.04 to 17.36. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #639 out of 952 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Biofil Chemicals & Pharmaceuticals' Operating Margin % too high?
Biofil Chemicals & Pharmaceuticals' current Operating Margin % of 4.76% is 54% above median its 10-year median of 3.09. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 17.36. The Drug Manufacturers industry median Operating Margin % is 7.58. Biofil Chemicals & Pharmaceuticals' value of 4.76% is 37.2% below this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #639 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #639 out of 952 companies for Operating Margin %. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median Operating Margin % is 7.58. Biofil Chemicals & Pharmaceuticals' value of 4.76% is 37.2% below this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own Operating Margin % has ranged from 1.04 to 17.36 over the past decade. While the company's 10-year median is 3.09 vs. the industry median of 7.58, Biofil Chemicals & Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current Operating Margin % of 4.76% is 37.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current Operating Margin % is 4.76%, which is 54% above median its own 10-year median of 3.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (BOM:524396) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.83, compared to a current price of ₹35.98 — trading 14% below its estimated fair value. The current Operating Margin % is 4.76%, which is 54% above median its 10-year median of 3.09 and 37.2% below the Drug Manufacturers industry median of 7.58. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (BOM:524396), the current Operating Margin % is 4.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (BOM:524396) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹35.98 is trading 14% below its estimated GF Value™ of ₹41.83.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:524396:
Operating Margin %: 4.76% (54% above median its 10-year median of 3.09)
GF Value™: ₹41.83 vs. price of ₹35.98 (14% below fair value)
Industry Position: 37.2% below the Drug Manufacturers median (#639 of 952)
No single metric tells the full story. See the BOM:524396 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
65GF Score
Get the complete analysis for BOM:524396
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524396 has been successfully added to your 
